Objective The aim of this study is to compare the frequency of remission, according to
DORIS definitions, of inception patients from two European SLE cohorts, with a special focus …

Introduction Despite available therapies, persistently active and corticosteroid-dependent
Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The …

Glucocorticoids (GCs) remain the cornerstone of the treatment of systemic lupus
erythematosus (SLE), despite advances in immunosuppressive drugs, therapeutic protocols …

Immune responses against endogenous nuclear antigens are characteristic of systemic
lupus erythematosus (SLE), a highly pleiomorphic disease predominantly affecting young …

The Hopkins lupus cohort is a longitudinal cohort study of over 2,000 systemic lupus
erythematosus (SLE) patients, who are seen quarterly. This review covers ten important …

The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE)
was the use of cyclophosphamide and methylprednisolone in the treatment of lupus …

Systemic lupus erythematosus (SLE) is a complex autoimmune multisystemic disease of
great clinical heterogeneity and significant potential morbidity and mortality. Although the …

Patients affected with systemic lupus erythematosus (SLE) display poor-long term prognosis
and increased mortality in respect of general population. This may be due to continuous …

Systemic lupus erythematosus (SLE) is an autoimmune disease of diverse manifestations,
with onset usually in young women in the third to fourth decade of life. The chronic nature of …

Despite advances in the treatment, patients with systemic lupus erythematosus (SLE) often
experience disease exacerbations (flares) of varying severity. Their diagnosis is primarily …